82 results
D
BTTX
Better Therapeutics Inc
23 Jan 24
$250.00 k in equity, sold $250.00 k, 1 investor
5:22pm
offering materials under this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
424B3
BTTX
Better Therapeutics Inc
10 Jan 24
Prospectus supplement
7:01am
by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
8-K
EX-10.1
BTTX
Better Therapeutics Inc
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall
424B3
BTTX
Better Therapeutics Inc
28 Dec 23
Prospectus supplement
9:23pm
to be significantly lower.
We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws health information … face substantial penalties.
We are subject to applicable fraud and abuse and other healthcare laws and regulations, including, without limitation
8-K
EX-10.1
oo0qehynq 9s9mt
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
D
in9rxaitx1331m7
11 Aug 23
$2.11 mm in equity, sold $2.11 mm, 10 investors
4:01pm
8-K
EX-10.2
8f8if2gyp8 1gjz7da2
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-10.1
5jemzp1va063sv6 77d
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm